Neurovive Pharmaceutical AB was dangling from the high wire after reporting a top-line analysis of the phase III CIRCUS study of Ciclomulsion, which indicated the study missed the primary clinical endpoint in patients with ST-segment elevation acute myocardial infarction (STEMI).